Verici Dx (LON:VRCI) Stock Price Down 17.2% – What’s Next?

Shares of Verici Dx plc (LON:VRCIGet Free Report) traded down 17.2% during trading on Friday . The stock traded as low as GBX 0.35 and last traded at GBX 0.35. 4,546,681 shares were traded during mid-day trading, an increase of 184% from the average session volume of 1,599,974 shares. The stock had previously closed at GBX 0.43.

Verici Dx Stock Down 17.2%

The company has a market capitalization of £5.33 million, a P/E ratio of -0.12 and a beta of 1.40. The company has a debt-to-equity ratio of 11.36, a quick ratio of 8.49 and a current ratio of 0.91. The firm’s fifty day moving average is GBX 0.46 and its 200-day moving average is GBX 0.61.

Verici Dx Company Profile

(Get Free Report)

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.

Featured Stories

Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.